SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 569.33 |
| Enterprise Value ($M) | 583.76 |
| Book Value ($M) | 341.65 |
| Book Value / Share | 6.05 |
| Price / Book | 1.67 |
| NCAV ($M) | 331.88 |
| NCAV / Share | 5.88 |
| Price / NCAV | 1.72 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.29 |
| Return on Assets (ROA) | -0.52 |
| Return on Equity (ROE) | -0.54 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 22.38 |
| Current Ratio | 22.38 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 351.86 |
| Assets | 361.64 |
| Liabilities | 19.98 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Vestal Point Capital, LP | 7.10 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 6.10 | 7.22 | |
| 13G/A | Fairmount Funds Management LLC | 9.90 | 61.48 | |
| 13G/A | Ra Capital Management, L.p. | 9.00 | 15.68 | |
| 13D/A | Perceptive Advisors Llc | 11.50 | 0.00 | |
| 13G/A | TCG Crossover GP II, LLC | 4.90 | -36.78 | |
| 13G/A | Fmr Llc | 15.00 | 26.40 | |
| 13G/A | Vanguard Group Inc | 4.67 | 0.00 | |
| 13G | BlackRock, Inc. | 6.20 | 0.00 | |
| 13G | Integrated Core Strategies (us) Llc | 5.20 | ||
| 13G/A | Cormorant Asset Management, LP | 0.00 | -100.00 | |
| 13G/A | Deep Track Capital, LP | 0.00 | -100.00 | |
| 13G/A | Vivo Opportunity, LLC | 4.50 | 47.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 43,693 | 222,912 | 19.60 | |
| 54,670 | 206,475 | 26.48 | |
| 33,513 | 159,768 | 20.98 | |
| 28,795 | 142,162 | 20.26 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ARCT – Arcturus Therapeutics Holdings Inc. | ARDX – Ardelyx, Inc. |
| ATAI – Atai Life Sciences N.V. | AUPH – Aurinia Pharmaceuticals Inc. |
| AURA – Aura Biosciences, Inc. |
Financial data and stock pages provided by
Fintel.io